Holen Sie sich die Stockscreener-App
6.78
0.15%
0.01
Schlusskurs vom Vortag:
$6.77
Offen:
$6.85
24-Stunden-Volumen:
347.86K
Relative Volume:
0.29
Marktkapitalisierung:
$192.65M
Einnahmen:
$157.75M
Nettoeinkommen (Verlust:
$-29.73M
KGV:
-5.8448
EPS:
-1.16
Netto-Cashflow:
$-21.00M
1W Leistung:
+8.48%
1M Leistung:
-5.83%
6M Leistung:
-54.16%
1J Leistung:
-64.22%
1-Tages-Spanne:
$6.70
$6.97
1-Wochen-Bereich:
$6.13
$6.99
52-Wochen-Spanne:
$5.85
$24.17
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
Firmenname
Arcturus Therapeutics Holdings Inc
Sektor
Branche
Telefon
(858) 900-2660
Adresse
10285 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Vergleichen Sie ARCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
6.78 | 192.36M | 157.75M | -29.73M | -21.00M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-24 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-10-23 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-10-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-09-04 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-05-28 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-01-28 | Eingeleitet | BTIG Research | Buy |
| 2024-08-12 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-13 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-07-24 | Eingeleitet | William Blair | Outperform |
| 2023-05-11 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-11-14 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-11-10 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2022-11-03 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-11-02 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-08-10 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2022-07-19 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-05-11 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2022-04-21 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-01-31 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-08-12 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2021-08-11 | Herabstufung | Goldman | Neutral → Sell |
| 2021-08-10 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2021-07-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-06-25 | Fortgesetzt | Goldman | Neutral |
| 2021-06-21 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-02-17 | Herabstufung | B. Riley Securities | Neutral → Sell |
| 2021-01-19 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-01-15 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-01-07 | Eingeleitet | Wells Fargo | Overweight |
| 2020-12-29 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-12-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-12-29 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-12-29 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-12-23 | Herabstufung | ROTH Capital | Buy → Sell |
| 2020-12-08 | Bestätigt | B. Riley Securities | Buy |
| 2020-12-07 | Bestätigt | B. Riley Securities | Buy |
| 2020-10-26 | Eingeleitet | Barclays | Overweight |
| 2020-10-06 | Eingeleitet | Citigroup | Buy |
| 2020-08-26 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-30 | Fortgesetzt | ROTH Capital | Buy |
| 2020-07-16 | Eingeleitet | Raymond James | Outperform |
| 2020-07-13 | Eingeleitet | B. Riley FBR | Buy |
| 2020-06-09 | Herabstufung | WBB Securities | Buy → Hold |
| 2020-02-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-02-07 | Eingeleitet | Guggenheim | Buy |
| 2020-02-06 | Eingeleitet | Guggenheim | Buy |
| 2019-04-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-09-20 | Hochstufung | WBB Securities | Buy → Strong Buy |
| 2018-01-22 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Arcturus Therapeutics Holdings Inc Aktie (ARCT) Neueste Nachrichten
1 Under-$10 Stock Set to Surge as Much as 963% in 2026 - Yahoo Finance
Will Arcturus Therapeutics Holdings Inc. stock maintain momentum in 2025Portfolio Profit Report & AI Driven Stock Movement Reports - ulpravda.ru
Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate - MSN
Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - BioSpace
Can Arcturus Therapeutics Holdings Inc. stock rebound after recent weaknessPortfolio Profit Report & Precise Entry and Exit Recommendations - ulpravda.ru
Is Arcturus Therapeutics Holdings Inc. stock positioned well for digital economyJuly 2025 Selloffs & Scalable Portfolio Growth Ideas - ulpravda.ru
mRNA drug developer Arcturus to share its work at major health conference - Stock Titan
Earnings Beat: Can Arcturus Therapeutics Holdings Inc. stock rebound after recent weaknessWeekly Earnings Recap & Real-Time Volume Surge Alerts - ulpravda.ru
Arcturus Therapeutics Holdings (ARCT): Analyst Ratings Suggest a Staggering 415% Upside Potential - DirectorsTalk Interviews
(ARCT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
UK Regulator OKs Arcturus Therapeutics' COVID-19 Booster Jab - MarketScreener
What analysts say about Arcturus Therapeutics Holdings Inc stockStraddle and Strangle Trades & Investment Case Studies - earlytimes.in
Arcturus Therapeutics Holdings files for mixed shelf of up to $500 millionSEC filing - MarketScreener
Arcturus Therapeutics Files $500 Million Mixed Shelf - MarketScreener
Precision Trading with Arcturus Therapeutics Holdings Inc. (ARCT) Risk Zones - Stock Traders Daily
Arcturus Therapeutics (ARCT) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
Will Arcturus Therapeutics Holdings Inc. stock benefit from infrastructure spending2025 Volume Leaders & Risk Controlled Daily Trade Plans - Улправда
How strong is Arcturus Therapeutics Holdings Inc. stock balance sheetMarket Activity Report & Weekly Watchlist of Top Performers - Улправда
How Arcturus Therapeutics Holdings Inc. stock reacts to job market dataTrade Risk Assessment & Weekly High Return Stock Forecasts - Улправда
Why Arcturus Therapeutics Holdings Inc. stock could outperform in 2025Weekly Market Report & Daily Momentum Trading Reports - DonanımHaber
How supply chain issues affect Arcturus Therapeutics Holdings Inc. stockWeekly Trend Recap & AI Enhanced Market Trend Forecasts - DonanımHaber
Arcturus Therapeutics Holdings Inc. Announces Management Changes - marketscreener.com
Arcturus Therapeutics CFO Andy Sassine to leave company - marketscreener.com
Arcturus Therapeutics announces CFO transition and interim appointment By Investing.com - Investing.com Australia
Arcturus Therapeutics Announces CFO Departure and Replacement - TipRanks
Arcturus Therapeutics announces CFO departure and replacement - MSN
Arcturus Therapeutics announces CFO transition and interim appointment - Investing.com
Arcturus Therapeutics Announces CFO Departure and Interim Appointment - TradingView — Track All Markets
Arcturus Therapeutics (NASDAQ:ARCT) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Institution Moves: How buyback programs support Comerica Incorporated Depositary Shares each stockJuly 2025 Spike Watch & Daily Technical Stock Forecast Reports - moha.gov.vn
Retail Surge: How interest rate cuts could boost Arcturus Therapeutics Holdings Inc stock 1; waitfor delay '0:0:15' - moha.gov.vn
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Arcturus Therapeutics Holdings Inc earnings missed by $3.55, revenue fell short of estimates - Investing.com Nigeria
ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know - MSN
Can Arcturus Therapeutics Holdings Inc. stock hit analyst price targetsJuly 2025 Outlook & Weekly Top Gainers Alerts - Newser
How Arcturus Therapeutics Holdings Inc. stock trades before earningsJuly 2025 Recap & AI Powered Buy and Sell Recommendations - Newser
(ARCT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Passes Below 200 Day Moving AverageShould You Sell? - MarketBeat
Guidance Update: How Arcturus Therapeutics Holdings Inc. stock reacts to job market dataNew Guidance & Safe Entry Momentum Stock Tips - moha.gov.vn
Wells Fargo Maintains Arcturus Therapeutics Holdings (ARCT) Overweight Recommendation - MSN
Will Arcturus Therapeutics Holdings Inc. stock deliver shareholder valueJobs Report & Weekly Watchlist of Top Performers - BỘ NỘI VỤ
Form 8-KCurrent report - ADVFN
Arcturus Therapeutics (NASDAQ:ARCT) Shares Pass Below 200 Day Moving AverageShould You Sell? - MarketBeat
Arcturus Therapeutics to Attend Upcoming Investor Conference - MarketScreener
Arcturus Therapeutics Hits 52-Week Low at $6.02 Amid Major Decline - Markets Mojo
Arcturus Therapeutics Hits 52-Week Low at $5.85 Amid Financial Struggles - Markets Mojo
Responsive Playbooks and the ARCT Inflection - Stock Traders Daily
What drives Arcturus Therapeutics Holdings Inc stock priceLow Beta Stocks & Free Trend Following Techniques - earlytimes.in
Is Arcturus Therapeutics Holdings Inc. stock a safe haven assetJuly 2025 Closing Moves & Stepwise Entry and Exit Trade Signals - newser.com
Finanzdaten der Arcturus Therapeutics Holdings Inc-Aktie (ARCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):